Risks of REVLIMID® (lenalidomide)

- REVLIMID is similar to the medicine thalidomide (THALOMID®). Thalidomide can cause severe life-threatening birth defects. If REVLIMID is used during pregnancy, it can cause birth defects or embryo-fetal death. REVLIMID must not be used by pregnant females and females who are able to get pregnant. Females who are able to get pregnant must avoid pregnancy while taking REVLIMID.
- REVLIMID causes low white blood cells (neutropenia) and low platelets (thrombocytopenia) in most patients.
- REVLIMID causes a higher chance for blood clots in your arteries (heart attacks and strokes), veins (deep vein thrombosis) and lungs (pulmonary embolism). To reduce this increased risk, most people who take REVLIMID will also take a blood thinner medicine.

REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low-or intermediate-1—risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
REVLIMID Risk Evaluation and Mitigation Strategy (REMS)™ program education and prescribing safety kit
**Prescriber quick reference guide**

1. The prescriber provides comprehensive counseling.
2. The prescriber verifies negative pregnancy test for **all** female patients of reproductive potential.
3. The prescriber completes REVLIMID® (lenalidomide) Patient-Physician Agreement Form with each patient and sends to Celgene.
4. Female patients complete initial mandatory confidential survey by:
   - Accessing the Celgene REMS mobile app
   - Calling Celgene Customer Care Center at **1-888-423-5436**

   Male patients do not need to complete the initial survey.

   **All patients** must complete subsequent mandatory confidential surveys as outlined in the Prescriber Guide to REVLIMID REMS™ Program (formerly known as the RevAssist® program).

5. The prescriber completes mandatory confidential survey and receives authorization number by:
   - Accessing the Celgene REMS mobile app
   - Calling Celgene Customer Care Center at **1-888-423-5436**

6. The prescriber writes REVLIMID prescription and includes authorization number and patient risk category.

7. The prescriber sends prescription to certified pharmacy.

This flow sheet should be used only as a quick reference and only after reviewing all of the REVLIMID REMS™ procedures.

**REVLIMID is only available under a restricted distribution program, REVLIMID REMS™.**

Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS, enclosed.

REVLIMID® is a registered trademark of Celgene Corporation. REVLIMID® is a trademark of Celgene Corporation.